Intraocular hemorrhage

	WikiDoc Resources for Intraocular hemorrhage
Articles
Most recent articles on Intraocular hemorrhage Most cited articles on Intraocular hemorrhage Review articles on Intraocular hemorrhage Articles on Intraocular hemorrhage in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Intraocular hemorrhage Images of Intraocular hemorrhage Photos of Intraocular hemorrhage Podcasts & MP3s on Intraocular hemorrhage Videos on Intraocular hemorrhage
Evidence Based Medicine
Cochrane Collaboration on Intraocular hemorrhage Bandolier on Intraocular hemorrhage TRIP on Intraocular hemorrhage
Clinical Trials
Ongoing Trials on Intraocular hemorrhage at Clinical Trials.gov Trial results on Intraocular hemorrhage Clinical Trials on Intraocular hemorrhage at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Intraocular hemorrhage NICE Guidance on Intraocular hemorrhage NHS PRODIGY Guidance FDA on Intraocular hemorrhage CDC on Intraocular hemorrhage
Books
Books on Intraocular hemorrhage
News
Intraocular hemorrhage in the news Be alerted to news on Intraocular hemorrhage News trends on Intraocular hemorrhage
Commentary
Blogs on Intraocular hemorrhage
Definitions
Definitions of Intraocular hemorrhage
Patient Resources / Community
Patient resources on Intraocular hemorrhage Discussion groups on Intraocular hemorrhage Patient Handouts on Intraocular hemorrhage Directions to Hospitals Treating Intraocular hemorrhage Risk calculators and risk factors for Intraocular hemorrhage
Healthcare Provider Resources
Symptoms of Intraocular hemorrhage Causes & Risk Factors for Intraocular hemorrhage Diagnostic studies for Intraocular hemorrhage Treatment of Intraocular hemorrhage
Continuing Medical Education (CME)
CME Programs on Intraocular hemorrhage
International
Intraocular hemorrhage en Espanol Intraocular hemorrhage en Francais
Business
Intraocular hemorrhage in the Marketplace Patents on Intraocular hemorrhage
Experimental / Informatics
List of terms related to Intraocular hemorrhage

	Intraocular hemorrhage;
ICD-10	H35.6
ICD-9	362.81
DiseasesDB	29369
MeSH	D012166

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Ocular Anatomy

The volume of the vitreous in the adult is about 4 cc or 80% of the volume of the eye's globe. Water makes up 99% of the vitreous content. The remaining 1% mostly is composed of collagen and hyaluronic acid which although clear, causes the vitreous to be gelatinous.

The vitreous is attached to the retina in three locations. The vitreous base refers to a 4 mm circular band where the vitreous body attaches to the anterior retina (ora serrata). This is the strongest of the three attachments. The vitreous also attaches in a circular zone around the optic nerve head. This is the second strongest attachment of the vitreous. This attachment becomes progressively weaker with advanced age, and it is this attachment that may become separated in posterior vitreous detachment.

The vitreous is itself avascular and therefore the blood in vitreous hemorrhage comes from organs outside the vitreous. When hemorrhage occurs into the vitreous, it accumulates in potential spaces within and around the vitreous body. These potential spaces for blood to accumulate include the following:

The retrolental space of Erggelet
The canal of Petit
The Cloquet canal
The bursa premacularis
The canal of Hannover (between the orbiculoanterocapsular and posterocapsular portions of the zonular fibers)

The borders of the vitreous body are as follows:

Posterior: The internal limiting membrane of the retina

Anterior: The nonpigmented epithelium of the ciliary body, and anteriorly by the lens zonular fibers and posterior lens capsule.

Pathophysiology

The two most common overarching pathophysiologic mechanisms of vitreous hemorrhage involve hemorrhage into the vitreous from a diseased retina or trauma. Specific pathophysiologic mechanisms are discussed below:

Extraocular Causes of Vitreal Hemorrhage

Diabetes and sickle cell disease are obvious extraocular diseases that are associated with retinopathy. Retinopathy is characterized by neovascular vessels, fragile vessels, occluded vessels and ischemic vessels, all of which increase the risk of vitreous hemorrhage. The disorders are associated with retinal ischemia which in turn causes the release of angiogenic growth factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factors (bFGF), and insulin-like growth factor (IGF).

Trauma is another major pathophysiologic mechanism of intraocular hemorrhage.

Conditions that may increase the risk of vitreal hemorrhage also include coagulation disorders (e.g. leukemia and thrombocytopenia). While coagulation disorders may not themselves be primarily associated with bleeding, in the presence of trauma or retinopathy they may secondarily increase the risk of bleeding. Autoimmune / collagen vascular disorders such as Behcets disease and sarcoid have also been associated with an increased risk of intraocular hemorrhage. Thus a careful history should be obtained regarding all these systemic / extraocular causes.

Subretinal Bleeeding with Breakthrough Bleeding into the Vitreous

Other less common pathological mechanisms of vitreous hemorrhage include subretinal bleeding with secondary extension into the vitreous cavity.

Age-related macular degeneration and choroidal melanoma are the two leading causes of vitreous hemorrhage secondary to breakthrough bleeding. Terson syndrome is subarachnoid hemorrhage associated with vitreous bleeding caused by rupture of retinal venules and/or capillaries as a result of a sudden increase in intracranial pressure (which is transmitted to the retinal vasculature via the optic nerve).

Subarachnoid Hemorrhage and Associated Intraocular Hemorhhage

Approximately one of three patients with subarachnoid hemorrhage will sustain an intraocular hemorrhage, and approximately 6% of patients have vitreous hemorrhage.

Terson Syndrome

In this condition, the branches of the central retinal vein or the central retinal vein itself are generally the source of intraocular bleeding. This syndrome occurs predominantly patients aged 30 to 50 years.